These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
89 related articles for article (PubMed ID: 2859024)
1. Receptor binding characteristics and pharmacokinetic properties as a tool for the prediction of clinical effects of beta-blockers. Wellstein A; Palm D; Belz GG; Pitschner HF Arzneimittelforschung; 1985; 35(1):2-6. PubMed ID: 2859024 [TBL] [Abstract][Full Text] [Related]
2. Correlation between pharmacological response, kinetics of plasma concentration and in vitro receptor affinities exemplified with beta-adrenoceptor blocking drugs. Wellstein A; Palm D Methods Find Exp Clin Pharmacol; 1984 Oct; 6(10):641-4. PubMed ID: 6151037 [TBL] [Abstract][Full Text] [Related]
3. [Pharmacological basis for the therapy of cardiovascular disease with beta-adrenoceptor blocking drugs (author's transl)]. Lemmer B Herz; 1982 Jun; 7(3):168-78. PubMed ID: 6124492 [TBL] [Abstract][Full Text] [Related]
4. Effects of (-)-RO363 at human atrial beta-adrenoceptor subtypes, the human cloned beta 3-adrenoceptor and rodent intestinal beta 3-adrenoceptors. Molenaar P; Sarsero D; Arch JR; Kelly J; Henson SM; Kaumann AJ Br J Pharmacol; 1997 Jan; 120(2):165-76. PubMed ID: 9117106 [TBL] [Abstract][Full Text] [Related]
5. Different changes of plasma membrane beta-adrenoceptors in rat heart after chronic administration of propranolol, atenolol and bevantolol. Horinouchi T; Morishima S; Tanaka T; Suzuki F; Tanaka Y; Koike K; Miwa S; Muramatsu I Life Sci; 2007 Jul; 81(5):399-404. PubMed ID: 17628611 [TBL] [Abstract][Full Text] [Related]
6. In vivo receptor binding of iodinated beta-adrenoceptor blockers. Eckelman WC; Gibson RE; Vieras F; Rzeszotarski WJ; Francis B; Reba RC J Nucl Med; 1980 May; 21(5):436-42. PubMed ID: 6103024 [TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamic models of various beta blockers: an explanation for the long duration of action of bopindolol. Grevel J J Cardiovasc Pharmacol; 1986; 8 Suppl 6():S16-9. PubMed ID: 2439812 [TBL] [Abstract][Full Text] [Related]
8. Stereospecific pharmacokinetics and pharmacodynamics of beta-adrenergic blockers in humans. Mehvar R; Brocks DR J Pharm Pharm Sci; 2001; 4(2):185-200. PubMed ID: 11466176 [TBL] [Abstract][Full Text] [Related]
9. In vitro receptor occupancy allows to establish equieffective doses of beta-blockers with different pharmacodynamic profiles in man. Investigations with propranolol and bufuralol. Wellstein A; Palm D; Matthews JH; Belz GG Methods Find Exp Clin Pharmacol; 1985 Dec; 7(12):645-51. PubMed ID: 3007897 [TBL] [Abstract][Full Text] [Related]
10. Radioligand binding studies with 3-(4-(2-hydroxy-3-((1, 1-dimethylethyl)-amino)-propoxy)-phenyl)-7-methoxy-2-methyl- 1(2H)-isoquinolinone (HI-42), a new cardioselective beta-adrenoceptor blocker with long-lasting effects in vivo. Jackisch R; Lederle M; Hertting G Arzneimittelforschung; 1985; 35(1A):237-40. PubMed ID: 2859028 [TBL] [Abstract][Full Text] [Related]
11. [Specific and nonspecific effects of beta receptor blockers: stereoselectively different properties exemplified by (R)- and (S)-propranolol]. Stoschitzky K; Lindner W Wien Med Wochenschr; 1990 Apr; 140(6-7):156-62. PubMed ID: 1971978 [TBL] [Abstract][Full Text] [Related]
12. A nonsteady-state agonist antagonist interaction model using plasma potassium concentrations to quantify the beta-2 selectivity of beta blockers. Jonkers R; van Boxtel CJ; Koopmans RP; Oosterhuis B J Pharmacol Exp Ther; 1989 Apr; 249(1):297-302. PubMed ID: 2565392 [TBL] [Abstract][Full Text] [Related]
13. Evolving mechanisms of action of beta blockers: focus on nebivolol. Mason RP; Giles TD; Sowers JR J Cardiovasc Pharmacol; 2009 Aug; 54(2):123-8. PubMed ID: 19528811 [TBL] [Abstract][Full Text] [Related]
14. The analysis of plasma kinetics and beta-receptor binding and -blocking activity of timolol following its small intravenous dose. Kaila T; Karhuvaara S; Huupponen R; Iisalo E Int J Clin Pharmacol Ther Toxicol; 1993 Jul; 31(7):351-7. PubMed ID: 8103764 [TBL] [Abstract][Full Text] [Related]
15. [Cardiac beta receptors--experimental aspects]. Kaumann AJ Z Kardiol; 1983 Feb; 72(2):63-82. PubMed ID: 6133398 [TBL] [Abstract][Full Text] [Related]
16. Mechanism-based pharmacodynamic modeling of S(-)-atenolol: estimation of in vivo affinity for the beta1-adrenoceptor with an agonist-antagonist interaction model. van Steeg TJ; Freijer J; Danhof M; de Lange EC J Pharmacol Exp Ther; 2008 Mar; 324(3):1234-42. PubMed ID: 18162599 [TBL] [Abstract][Full Text] [Related]
17. Pharmacology of beta-blockers: classical aspects and recent developments. Haeusler G J Cardiovasc Pharmacol; 1990; 16 Suppl 5():S1-9. PubMed ID: 11527109 [TBL] [Abstract][Full Text] [Related]
18. Haemodynamic consequences of intrinsic sympathomimetic activity in relation to changes in plasma renin activity and noradrenaline during beta-blocker therapy for hypertension. Man in't Veld AJ; Schalekamp MA Postgrad Med J; 1983; 59 Suppl 3(689):140-58. PubMed ID: 6139800 [TBL] [Abstract][Full Text] [Related]